SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: FINAL 2-YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 2

Young-Suk Lim, Chun-Yen Lin, Jeong Heo, Ho Bae, Wan-Long Chuang, Tak Yin, Owen Tsang, Claire Fournier, Aric Josun Hui, Huy Trinh, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, John F. Flaherty, Vithika Suri, Anuj Gaggar, Dianna M. Brainard, Stephen Ryder, Harry La Janssen

Research output: Contribution to journalJournal Article peer-review

Original languageAmerican English
JournalGut
Volume70
DOIs
StatePublished - 2021

Cite this